These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Identification of a novel mutation in the ryanodine receptor gene (RYR1) in patients with malignant hyperthermia. Rueffert H; Kraus H; Olthoff D; Deutrich C; Froster UG Hum Mutat; 2001 Mar; 17(3):238. PubMed ID: 11241852 [No Abstract] [Full Text] [Related]
4. Novel mutations at a CpG dinucleotide in the ryanodine receptor in malignant hyperthermia. Manning BM; Quane KA; Lynch PJ; Urwyler A; Tegazzin V; Krivosic-Horber R; Censier K; Comi G; Adnet P; Wolz W; Lunardi J; Muller CR; McCarthy TV Hum Mutat; 1998; 11(1):45-50. PubMed ID: 9450902 [No Abstract] [Full Text] [Related]
5. RYR1 variant c.38T>G, p.Leu13Arg causes hypersensitivity of the ryanodine receptor-1 and is pathogenic for malignant hyperthermia. van den Bersselaar LR; Greven T; Bulger T; Voermans NC; van Petegem F; Schiemann AH; Parker R; Burling SM; Jungbluth H; Stowell KM; Kamsteeg EJ; Snoeck MMJ Br J Anaesth; 2021 Aug; 127(2):e63-e65. PubMed ID: 34127251 [No Abstract] [Full Text] [Related]
6. King-denborough syndrome caused by a novel mutation in the ryanodine receptor gene. D'Arcy CE; Bjorksten A; Yiu EM; Bankier A; Gillies R; McLean CA; Shield LK; Ryan MM Neurology; 2008 Sep; 71(10):776-7. PubMed ID: 18765655 [No Abstract] [Full Text] [Related]
7. Statin-induced adverse effects and malignant hyperthermia susceptibility: comment on the article by Guis et al. Vladutiu G Arthritis Rheum; 2007 Feb; 57(1):186-7; author reply 187-8. PubMed ID: 17266123 [No Abstract] [Full Text] [Related]
8. Myopathic changes in malignant hyperthermia-susceptible patients. Rosenberg H Can J Anaesth; 2013 Oct; 60(10):955-9. PubMed ID: 23897489 [No Abstract] [Full Text] [Related]
9. The genetics of malignant hyperthermia and related muscular syndromes. Siracusano L; Girasole V Anesth Analg; 2010 Apr; 110(4):1241; author reply 1241. PubMed ID: 20357163 [No Abstract] [Full Text] [Related]
10. Skeletal muscle ryanodine receptor mutations associated with malignant hyperthermia showed enhanced intensity and sensitivity to triggering drugs when expressed in human embryonic kidney cells. Sato K; Roesl C; Pollock N; Stowell KM Anesthesiology; 2013 Jul; 119(1):111-8. PubMed ID: 23459219 [TBL] [Abstract][Full Text] [Related]
11. Ryanodine receptor type 1 gene mutations found in the Canadian malignant hyperthermia population. Kraeva N; Riazi S; Loke J; Frodis W; Crossan ML; Nolan K; Kraev A; Maclennan DH Can J Anaesth; 2011 Jun; 58(6):504-13. PubMed ID: 21455645 [TBL] [Abstract][Full Text] [Related]
12. Identification of a novel mutation in the ryanodine receptor gene (RYR1) in a malignant hyperthermia Italian family. Fortunato G; Berruti R; Brancadoro V; Fattore M; Salvatore F; Carsana A Eur J Hum Genet; 2000 Feb; 8(2):149-52. PubMed ID: 10757649 [TBL] [Abstract][Full Text] [Related]
15. Continued progress in understanding the molecular genetics of malignant hyperthermia. Rosenberg H Can J Anaesth; 2011 Jun; 58(6):489-93. PubMed ID: 21455644 [No Abstract] [Full Text] [Related]
16. Association of a mutation in the ryanodine receptor 1 gene with equine malignant hyperthermia. Aleman M; Riehl J; Aldridge BM; Lecouteur RA; Stott JL; Pessah IN Muscle Nerve; 2004 Sep; 30(3):356-65. PubMed ID: 15318347 [TBL] [Abstract][Full Text] [Related]
17. Functional studies of RYR1 mutations in the skeletal muscle ryanodine receptor using human RYR1 complementary DNA. Sato K; Pollock N; Stowell KM Anesthesiology; 2010 Jun; 112(6):1350-4. PubMed ID: 20461000 [TBL] [Abstract][Full Text] [Related]
18. A fulminant malignant hyperthermia episode in a patient with ryanodine receptor gene mutation p.Tyr522Ser. Girard T; Suhner M; Levano S; Singer M; Zollinger A; Hofer CK Anesth Analg; 2008 Dec; 107(6):1953-5. PubMed ID: 19020143 [TBL] [Abstract][Full Text] [Related]